Granted Patent B2

US 12,427,140 · App. 17/604,750 · Granted Sep 30, 2025

Inventor: Claes Thulin (Stockholm, SE)

A61K31/4439A61K45/06A61P19/02A61P29/00

Abstract

Claims (37)

1. A method of treating pain from osteoarthritis in a dog, comprising:

administering to a dog in need thereof an effective amount of a compound selected from the group consisting of: 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT00), 4-[5-[(1R)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine, (TT001) and 4-[5-[(1S)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT002), and combinations thereof, or a pharmaceutically acceptable salt thereof, enantiomer, or mixture thereof;

wherein said dog has osteoarthritis and the pain is a direct result of the osteoarthritis.

2. The method according to claim 1 , wherein the pain is peripheral pain.

3. The method according to claim 1 , wherein the pain is chronic pain.

4. The method according to claim 1 , wherein said dog has gastroesophageal reflux disease (GERD) and

wherein the administering treats the GERD.

5. The method according to claim 1 , wherein said dog has anxiety and

wherein the administering treats the anxiety.

6. A method of treating pain from osteoarthritis in a dog, comprising:

administering to a dog in need thereof an effective amount of a compound selected from the group consisting of: 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT00), 4-[5-[(1R)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine, (TT001) and/or 4-[5-[(1S)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT002), and combinations thereof, or a pharmaceutically acceptable salt thereof, enantiomer, or mixture thereof, in combination with a pharmaceutically acceptable adjuvant, diluent or carrier

wherein said dog has osteoarthritis and the pain is a direct result of the osteoarthritis.

7. The method according to claim 6 ,

wherein said dog has gastroesophageal reflux disease (GERD) and

wherein the administering treats the GERD.

8. The method according to claim 6 , wherein the compound is administered in a pharmaceutical composition, comprising a pharmaceutically acceptable adjuvant, diluent or carrier,

wherein said dog has anxiety, and

wherein the administering treats the anxiety.

9. A method of treating pain from osteoarthritis in a subject dog comprising:

administering a pharmaceutical composition comprising (i) compounds 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT00), 4-[5-[(1R)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine, CAS Number 934282-55-0 (TT001) and/or 4-[5-[(1S)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT002), or a pharmaceutically acceptable salt thereof, enantiomer, or mixture thereof, and a pharmaceutically acceptable excipient, carrier or diluent, and (ii) at least one additional therapeutic agent selected from the group consisting of anesthetic, NSAID and opiates, and a pharmaceutically acceptable excipient, carrier, and-diluent, for use in treatment of peripheral pain or chronic and peripheral pain related to osteoarthritis in dogs;

wherein said dog has osteoarthritis and the pain is a direct result of the osteoarthritis.

10. A method of treating pain from osteoarthritis in a subject dog comprising:

administering a pharmaceutical composition comprising (i) compounds 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT00), 4-[5-[(1R)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine, (TT001) and/or 4-[5-[(1S)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT002), or a pharmaceutically acceptable salt thereof, enantiomer, or mixture thereof, (ii) an additional therapeutic agent, or a pharmaceutically acceptable salt thereof, and (iii) a pharmaceutically acceptable excipient, carrier or diluent

wherein said dog has osteoarthritis and the pain is a direct result of the osteoarthritis.

11. The method of claim 9 :

wherein said dog has gastroesophageal reflux disease (GERD) and

wherein the administering prevents and treats the GERD.

12. The method of claim 9 wherein said dog has anxiety, and wherein the administering treats the anxiety.

13. The method according to claim 10 , wherein the additional therapeutic agent is an anesthetic, NSAID or opiate.

14. The method according to claim 9 , wherein the additional therapeutic agent is an NSAID selected from the group comprising butyl pyrazolidines, oxicams, propionic acid derivative, fenamic acid and coxibs.

15. The method according to claim 9 , wherein the additional therapeutic agent is an anesthetic selected from the group comprising acepromazine, morphine or propofol.

16. The method according to claim 9 , wherein the additional therapeutic agent is an opiate.

17. The method according to claim 1 , wherein the compound is TT001, or a hydrochloride or sulphate salt thereof.

18. The method according to claim 1 , wherein the selected compound is administered to a dog at a dose of 0.1 to 5.0 mg/kg.

19. The method according to claim 1 , wherein the selected compound is administered to a dog at a dose of 0.1 to 1.0 mg/kg, once daily.

20. The method according to claim 1 , wherein the selected compound is administered to a dog at a dose of 0.1 to 0.5 mg/kg, twice daily.

21. The method according to claim 1 , wherein compound TT001 is administered to a dog at a dose of 0.1 to 1.0 mg/kg, once daily.

Priority Claims (1)

Continuity (1)

References Cited (29)